RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to sell shares; the loss of the value of investment; and dilution of shareholding. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme.
Please read full risk warnings.
View our deals
Discovering and developing soloMER™s for the treatment of auto-immune mediated, inflammatory diseases.
Sector: Drug discovery and Biopharma
Region: UK: Scotland
Eligible Tax: EIS
Hurricane Modular Commerce Ltd.
Developed and launched a duty and tax engine for e-commerce participants.
Sector: Business enterprise software
Region: UK: South West
Eligible Tax: EIS
Developed a suite of portable, multi-parameter, non-invasive, hand-held emergency vital signs monitors. “Where Emergency Medicine Begins.”
Region: Glasgow, Scotland
Eligible Tax: EIS
Touch Biometrix Ltd.
“A revolution in Fingerprint Biometrics”
Sector: Electronics & Hardware
Region: UK: Wales & Netherlands: Eindhoven
Stage: Growth – pre-revenue
Eligible Tax: EIS
Innovative mobile surveillance platform, for the heavily regulated global financial services industry.
Region: London, UK
Eligible Tax: EIS
vTime Holdings Ltd
Developed an innovative and multi-user communication, entertainment and engagement platform for VR and AR
Region: UK: North-West
Eligible Tax: EIS
Region: UK: North-West
Eligible Tax: EIS
Deepbridge Syndicate allows eligible investors to invest alongside the highly qualified specialists at Deepbridge into high growth life science and disruptive technology companies.
Expertise: Access to Life Sciences and Technology companies who have been through extensive due diligence, leveraging over 200 years combined experience by Deepbridge’s specialist team; investors can be confident of realistic company valuations, market need and potential for growth.
Hands-on Management: Deepbridge takes a proactive approach to managing underlying investee companies, taking a board position to ensure they are developing as planned and in the best interest of investors.
Online Investment Platform: Investors can build and monitor their own portfolio of high growth companies, with access to company financials, video presentations, regular updates and much more, through their online profile.
Tax Efficient Investing: Unless otherwise stated, all companies featuring on Deepbridge Syndicate are EIS eligible, thereby mitigating some of the investment risk for our investors.
Investor Fee Free: We do not charge investors any fees at the point of investment, therefore investors enjoy 100% of EIS tax benefits and have 100% of their investment actually put to work earning investment returns.
Providing funding to the companies who are working to improve our lives and the lives of our future generations offers much more than just a financial opportunity.
Deepbridge Syndicate is an investor fee free proposition.
Investors are not charged any fees at the point of investment allowing investors to enjoy 100% of EIS tax benefits and 100% of their investment put to work earning investment returns.
About Deepbridge Syndicate
We want to offer experienced investors the opportunity to make well-informed, personal decisions on which innovative life sciences and disruptive technology companies to invest in, with all the added reassurance brought with specialist, hands-on investment managers.
Investing in Life Sciences
Investing in Life Sciences is different.
It is not always as obvious to see the exit opportunities, understand the nuances of the technology or value the proposition – but the potential of this sector is considerable. We think private investors should have the opportunity to get involved at the early stages, support the advancement of healthcare and reap the rewards from this continuously growing sector.
Investing in disruptive technology
Backing companies creating new markets or with potential to displace the incumbent
New technologies are changing how we live and work, how we interact with each other. Deepbridge aims to identify technology growth companies that have a proven technology, robust intellectual property and are operating in a high growth market sector. Deepbridge believe these companies can typically accelerate rapidly, generating encouraging results within a medium to long-term time frame.
Deepbridge Syndicate has been developed to open up opportunities to individuals which have traditionally have been reserved for institutional investors. By working alongside Deepbridge’s highly experienced specialists, all companies have been through thorough due diligence and valuation by a team with over 200 years worth of combined cross-sector commercial experience, and will have ongoing guidance, mentoring and support from the team for the lifetime of the investment.
Meet Our Team
With over 200 years combined experience, the Management team has ultimate responsibility for the management of Deepbridge Syndicate. The Partners will identify, appoint and co-ordinate any necessary employees, contractors and advisers, taking the key commercial and legal decisions and resolving issues to ensure that the strategic expansion is executed efficiently and seamlessly.
A successful entrepreneur and CEO with more than two decades of leading private and public companies, Ian has successfully led the turnaround, re-capitalisation and listing of several businesses, returning them to profit.
He currently holds personal investments in a number of technology companies whose new products are in the proof of concept stage. He holds a Business Education Diploma from the University of Newcastle, and a Licentiateship (LCGI) (NVQ Level 4) from the Royal Navy.
Savvas is the Head of Life Sciences at Deepbridge. Prior to joining Deepbridge, Savvas enjoyed a 15 year career in the City, working as an investment banker at JP Morgan, Bear Stearns, Shore Capital, Cantor Fitzgerald, and Panmure Gordon. Savvas was also CEO of telemedicine business Now Healthcare Group. As a highly acclaimed analyst, Savvas has won multiple awards, most recently in 2015 when Savvas was ranked 2nd overall in the prestigious Reuters Starmine survey, a position he also held in 2014. In the same year, Savvas was also runner-up in the CityAM Analyst of the Year awards.
Savvas holds a PhD in psychopharmacology from Nottingham University and a BSc (Hons) degree in pharmacology from Manchester University.
Over 20 years of experience in the biotechnology sector, Chris has founded, managed and successfully exited two biotechnology companies, Bioenvision Inc. (NASDAQ:BIV, which grew to a market capitalization of $345 million, and was acquired by Genzyme Corporation in October 2007), and Medirace Limited (later Medeva PLC, traded on both the London Stock Exchange and the New York Stock Exchange, and subsequently acquired by Celltech Group PLC, now UCB, for £554 million).
An Honorary Professor at Imperial College London, Chris holds an M.D. from the University of Wales School of Medicine, and is a Fellow of the Royal College of Surgeons of Edinburgh.
With a wealth of experience in financial services, including institutional fund management within the Lloyd’s of London insurance community, and HNW private client stockbroking at Popes Stockbrokers (now Brewin Dolphin), Kieran has an in-depth knowledge of the private capital markets, involving capital raising, investor relations and communication, and is responsible for the technical aspects of the EIS and SEIS operations at Deepbridge.
Kieran has been a Fellow of the Chartered Institute of Securities and Investments since 2001. Through his position on the Investment Supervisory Committee, Kieran acts as a conduit between the Executive Team at Deepbridge and the Independent Committee Team, thus ensuring the Independent Committee have access to all information required to assist them in making sound and strategic investment decisions on a timely basis.
As Senior Technology Adviser, Matthias assists in the appraisal and assessment of new technologies, as part of the investment appraisal and management process, within the Deepbridge Renewable Energy Team. Matthias has more than 20 years’ experience in the IT and Systems Integration sector, as well as vast experience in innovation-led
technology engineering. Matthias holds a Masters in Mechanical Engineering from the Technology University in Munich, and a degree in Computer Science from Trinity College, Dublin.
Fuchsia manages Deepbridge Syndicate, the online capital raising platform of Deepbridge enabling private investors to invest directly into single Life Science EIS companies, alongside the specialists at Deepbridge. With a degree in Financial and Business Economics from Newcastle University, prior to joining Deepbridge Fuchsia was Client Relationship and Business Development Manager at AngelNews, a leading venture capital focussed news service and national events company for private investors and the companies they invest in.
With a wealth of experience in the venture capital sector, Fuchsia was also a co-founder and inaugural committee member of Greenshoots, the junior branch of the Enterprise Investment Scheme Association (EISA).
As Head of Marketing, Andrew oversees all Deepbridge communications and messaging. Andrew has a wealth of experience marketing financial and professional institutions, with over a decade of experience building credible brands and delivering real growth.
Andrew is a Member of The Chartered Institute of Marketing and holds a BSc in Business Economics and Marketing from the University of Wales, Aberystwyth. Andrew is also a trustee of the Tim Parry Johnathan Ball Foundation For Peace.
Ray is an experienced capital markets professional having spent over two decades working for some of the largest banks and broking houses in the world.
He has held senior positions across a variety of disciplines including; trading, portfolio management, private banking and corporate finance with institutions such as Garban Intercapital (now ICAP), Prudential-Bache, Barclays Wealth, and Coutts & Co.
Ray works closely with sophisticated investors, private offices and institutional funding partners, as well as providing corporate finance support to later-stage portfolio investee companies.
With a Masters in Computer Science from Trinity College Dublin and a MBA from Dublin City University, Adrian has considerable experience of working with tech-focussed innovations and developing digital strategies.
Adrian’s previous roles include 10 years as IT Director at Hewlett Packard followed by the role of CEO at the Irish Greyhound Racing Board, where he led the digitisation of operations.
Most recently, since 2014, Adrian has been Commercial Director at Trinity College Dublin.
Nagy Habib is Professor of Hepatobiliary Surgery, at the Department of Cancer Surgery, at Imperial College London. With principal research activities focusing on the improvement of surgical technologies, Nagy has also been instrumental in the development of remediation and/or cure of diseases of the liver as either a complement or replacement to surgery with particular focus on gene therapy, the use of stem cells and immunotherapy.
Nagy has also pioneered novel clinical trials for the treatment of liver cancer. Nagy has extensively published on a wide range of related topics, and is the inventor of, and co-author of the ﬁrst publication about the use for, radiofrequency in devices used in liver surgery. Awarded by the Advisory Committee for Clinical Excellence, which is given in recognition of exceptional contributions from NHS consultants, Nagy has been named as one of Britain’s top surgeons by the Saturday Times Magazine in 2011.
Gary graduated from Trinity College, Dublin with MB BCh BAO, in 1997. Subsequently he undertook training in various medical specialities prior to being awarded AFRCSI from Royal College of Surgeons, Ireland in 2001.
Subsequently he undertook general practice training in the Mersey Deanery and was awarded Merit in the MRCGP examinations 2006. Further he studied at Manchester University to obtain Certificate of Occupational Health.
Gary has been a GP Principal and Partner in an 8000 patient practice in Cheshire. This experience gives him an understanding of front-line medical services and a distinct insight into the needs of patients and clinicians. Gary is also clinical lead for Primary Care, a Governing Body member at Halton CCG and has been selected to study on the Nye Bevan program at the NHS leadership Academy.
Liz has a degree in Chemistry and a DPhil in Physical Chemistry from the University of Oxford. She joined the commercial team in a start-up company spun-out of Oxford
University, and built-up expertise in intellectual property management and IP strategy. Later Liz spent 7 years at the University of Reading as their IP/Legal Advisor. Then in 2012 Liz joined Science & Technology Facilities Council as Licensing Manager. She is based at the STFC Rutherford Appleton Laboratory and now forms part of the STFC innovation management team with responsibility for a portfolio of spin-out companies and licensing deals at both Rutherford Appleton Laboratory and Sci-Tech Daresbury.
Geoff is the Chief Executive of Bionow, the life sciences membership organisation for the North of England. Having founded the business in 2011, Bionow has 15 University members and 300 industry members across the North of England and North Wales.
Geoff is regularly invited to advise and comment on industry requirements and represent the Bionow membership both regionally and nationally. Previously, Geoff founded 2 biotech companies, Biorite Ltd and Advanced Biomedical Ltd, both spinout companies from the University of Manchester focused on developing point of care diagnostic technologies. Geoff has a degree in Biochemistry and a PhD from the School of Pharmacy, University of Manchester where he began his career undertaking postdoctoral research in the area of enhanced payload responsive liposomal drug delivery systems. Geoff is also a Board Member and Treasurer of the Academy of Pharmaceutical Sciences, a member of the Liverpool LEP Health and Life Sciences Advisory Board, member of Health Innovation Manchester Exec group and member of Northeast LEP Health and Life Sciences Advisory Board.
Lloyd co-founded, launched and scaled Zesty from an idea in July 2012 into one of the UK’s leading Digital Health companies, winning multiple awards and raising in excess of $10M in funding.
Zesty was selected as “1 of the UK’s 30 Finest Early Stage Technology Businesses” by TechCityUK for the Upscale program in 2015 and subsequently Lloyd was voted “1 of the 100 most influential people in HealthTech globally” in 2016 by HotTopics magazine.
Prior to his 5 years in Healthcare, Lloyd had 15 years’ experience building Digital Businesses within 6 Industries – Retail, Travel, Finance, Advertising, Dating and Social Networking. Lloyd studied Business Administration at Coventry University and Corporate Finance at London Business School.
Rebecca is a paediatric surgeon at the Bristol Royal Hospital for Children. A member of the Royal College of Surgeons (England) and the British Association of Paediatric Surgeons, she has experience in surgical and medical settings in India, Tanzania, South Africa and Cambodia.
Graduating from The University of Sheffield Medical School, Rebecca also holds a Masters’ in Health Research from the University of Lancaster and the Diploma in Tropical Medicine & Hygiene from the London School of Hygiene & Tropical Medicine. She is an Advanced Paediatric Life Support Instructor and has presented her research at many national and international surgical conferences.
Invest alongside the specialists
Deepbridge Syndicate allows eligible investors to invest alongside the highly qualified life sciences and tech specialists at Deepbridge. Benefiting from Deepbridge’s extensive due diligence and sector knowledge; investors can be confident of realistic company valuations and be reassured by Deepbridge’s proactive ongoing management of investee companies.